Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer

Cancer Immunology, Immunotherapy

Volumn 63, Issue 9, 2014, Pages 939-946

  Chung, Moon Jae ^a   Park, Jeong Youp ^a   Bang, Seungmin ^a   Park, Seung Woo ^a   Song, Si Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adoptive immunotherapy; Cytokine induced killer cells; Gemcitabine refractory; Pancreatic cancer

Indexed keywords

GEMCITABINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; DEOXYCYTIDINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BODY IMAGE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOKINE INDUCED KILLER CELL; EX VIVO STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; JAUNDICE; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEXUALITY; TREATMENT DURATION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CYTOKINE-INDUCED KILLER CELLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84906938534     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1566-3     Document Type: Article

References (29)

1. National Cancer Information Center (2013) Cancer Information Service National Cancer Information Center. http://www.cancer.go.kr/mbs/cancer/subview. jsp?id=cancer-040201000000. Accessed 12 Aug 2013
2. Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68-72
3. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B et al (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645-1651
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
5. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237
6. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ et al (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610
7. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for secondline advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681
8. Jin J, Joo KM, Lee SJ, Jo M, Kim Y, Jin Y et al (2011) Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep 25:33-39
9. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale Schianca F et al (2012) Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12:673-684
10. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305-310
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655 (Pubitemid 13149996)
12. Schmidt Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139-149
13. Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K et al (2007) Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol 7:1793-1801 (Pubitemid 350054927)
14. Kim HM, Lim J, Park S, Kang JS, Lee CW, Lee KH et al (2007) Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 7:1802-1807 (Pubitemid 350054928)
15. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K, Kakizoe T (1993) A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47:73-78 (Pubitemid 23179962)
16. Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y et al (2011) Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol 138:23-32
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376 (Pubitemid 23073154)
19. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg A, Bassi C et al (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35:939-941 (Pubitemid 29277128)
20. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181 (Pubitemid 36962641)
21. Boeck S, Weigang Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J et al (2007) Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18:745-751 (Pubitemid 46523280)
22. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481-485 (Pubitemid 43289750)
23. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792 (Pubitemid 350086482)
24. Oh SY, Kim HJ, Kim TH, Lee G, Jeong C, Kwon H et al (2010) Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer. Invest New Drugs 28:343-349
25. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii Saab T, Pluard T et al (2010) A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15:1310-1319
26. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E et al (2013) A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 109:920-925
27. Zabernigg A, Giesinger JM, Pall G, Gamper EM, Gattringer K, Wintner LM et al (2012) Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer 12:390
28. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, van der Burg SH et al (2010) Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 70:8339-8346
29. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J et al (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802-807